资讯

Precision Medicine Online14 小时
KSQ Begins Dosing Patients With Gene-Edited TIL Therapy in Phase I/II Trial
The firm is hoping that the CRISPR/Cas9-edited TILs will have anti-tumor activity with long-term persistence against various solid tumors.